The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure

Trial Profile

The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2016 Planned End Date changed from 1 Jul 2014 to 1 Aug 2017.
    • 08 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 14 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top